Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00358332
Other study ID # 05-0146
Secondary ID U19AI0656832U01A
Status Completed
Phase Phase 1
First received July 27, 2006
Last updated October 18, 2011
Start date November 2006
Est. completion date December 2007

Study information

Verified date October 2011
Source U.S. Army Medical Research and Materiel Command
Contact n/a
Is FDA regulated No
Health authority Mali: University of Bamako Faculty of Medicine Institutional Review BoardUnited States: Institutional Review BoardUnited States: Federal GovernmentUnited States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test the safety and dosages of a malaria vaccine in 100 children, 1-6 years old, in Bandiagara, Mali. The study is testing the safety of the vaccine when it is given to people who are regularly exposed to malaria and it will provide information regarding optimal vaccine dosage. This study will compare 3 injections of different vaccine doses to a rabies vaccine that is already approved. During the study, the child's health will be checked in the clinic and during home visits. Children may participate for about 14 months, and blood will be taken from each child throughout the study. If the child becomes sick from malaria, he/she will be treated. Information from this study may be used to develop a malaria vaccine that will help control the disease.


Description:

This study is a randomized, controlled, dose-escalation, phase I trial of the FMP2.1/AS02A malaria vaccine, using rabies vaccine as a control. This study is linked to DMID protocol 07-0003. The primary objective of this study is to evaluate the safety and reactogenicity of FMP2.1/AS02A in children naturally exposed to P. falciparum malaria infection. The secondary objective is to measure the magnitude and duration of antibody response to FMP2.1 by enzyme-linked immunosorbent assay (ELISA). One hundred healthy children aged 1-6 years in Bandiagara, Mali, will be randomized to 1 of 3 possible groups. Twenty subjects will be enrolled in cohort 1 and 40 subjects each in cohorts 2 and 3. Children within each cohort will be randomized in a 3:1 ratio to receive 10, 25 or 50 micrograms of FMP2.1 (in cohorts 1, 2 and 3, respectively) adjuvanted with a proportionate volume of the AS02A, or rabies vaccine. Thus a total of 75 children will receive the malaria vaccine and 25 the rabies vaccine. Immunizations will be given on days 0, 30 and 60 in a staggered fashion, with the first administrations of the 25 and 50 microgram dose levels of FMP2.1 following the first administration of the 10 and 25 microgram dose levels, respectively, by 2-3 weeks. Solicited adverse events will be recorded on the days of immunization and days 1, 2, 3 and 7 after each immunization, and unsolicited adverse events will be recorded for 30 days after each immunization. Children will be followed for 1 year after the last immunization. Sera will be collected for anti-FMP2.1 antibody titers on the days of immunization and 14 days after each immunization as well as 3, 6, 9 and 12 months after the first immunization. Each child will participate in the study for up to 414 days, which includes the screening period. The primary outcome measures include: occurrence of solicited symptoms after each vaccination during a 7-day surveillance period (day of vaccination and days 1, 2, 3 and 7 after vaccination), occurrence of unsolicited symptoms after each vaccination during a 30-day surveillance period (day of vaccination and 30 subsequent days); and occurrence of serious adverse events throughout the study period. The secondary outcome measure is titers and activity of anti-FMP2.1 antibody at each time point where serology samples are analyzed, measured by ELISA.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 2007
Est. primary completion date December 2007
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 1 Year to 6 Years
Eligibility Inclusion Criteria:

- Age 1-6 years inclusive at the time of screening.

- Residing in Bandiagara town.

- Appear to be in generally good health based on clinical and laboratory investigation.

- Separate written informed consent obtained from the parent/guardian before screening and study start, respectively.

- Available to participate in follow-up for the duration of study (14 months).

Exclusion Criteria:

- Previous vaccination with an investigational vaccine or a rabies vaccine.

- Use of a investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first study immunization, or planned use up to 30 days after the third immunization.

- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first immunization. This includes any dose level of oral steroids or inhaled steroids, but not topical steroids.

- Confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.

- Confirmed or suspected autoimmune disease.

- History of allergic reactions or anaphylaxis to immunizations or to any vaccine component.

- History of serious allergic reactions to any substance, requiring hospitalization or emergent medical care.

- History of allergy to tetracycline, doxycycline, nickel or Imidazole.

- History of splenectomy.

- Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than the upper limit of normal of the testing laboratory = 49.6 U/L).

- Laboratory evidence of renal disease (serum creatinine greater than the upper limit of normal of the testing laboratory = 0.5 mg/dL (44.2 micromol/L), or more than trace protein or blood on urine dipstick testing).

- Laboratory evidence of hematologic disease (absolute leukocyte count <5,300/mm^3 or >15,300/mm^3, absolute lymphocyte count <2,300 mm^3, platelet count <133,000/mm^3, or hemoglobin <9.0 g/dL).

- Chronic skin condition that could interfere with vaccine site reactogenicity assessment.

- Administration of immunoglobulins and/or any blood products within the three months preceding the first study immunization or planned administration during the study period.

- Simultaneous participation in any other interventional clinical trial.

- Acute or chronic pulmonary, cardiovascular, hepatic, renal or neurological condition, severe malnutrition, or any other clinical findings that in the opinion of the Principal Investigator (PI) may increase the risk of participating in the study.

- Other condition that in the opinion of the PI would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention


Intervention

Biological:
FMP2.1/AS02A
FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
Rabies vaccine (RabAvert)
RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.

Locations

Country Name City State
Mali University of Bamako, Malaria Research and Training Center Bamako

Sponsors (5)

Lead Sponsor Collaborator
U.S. Army Medical Research and Materiel Command GlaxoSmithKline, National Institute of Allergy and Infectious Diseases (NIAID), University of Maryland, Walter Reed Army Institute of Research (WRAIR)

Country where clinical trial is conducted

Mali, 

References & Publications (1)

Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Kone AK, Guindo AB, Traore K, Sissoko M, Diallo DA, Diarra I, Kouriba B, Daou M, Dolo A, Baby M, Sissoko MS, Sagara I, Niangaly A, Traore I, Olotu A, Godeaux O, Leach A, Dubois MC, Ballou WR, Cohen J, Thompson — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of Solicited Systemic Symptoms During a 7-day Surveillance Period (Systematically Collected) Following Vaccinations at Days 0, 30, and 60. The number of participants reporting drowsiness irritability/fussiness, loss of appetite, vomiting, and feverishness. Participants are counted only once but may have experienced symptoms on multiple occasions. 7 Days following any vaccination Yes
Primary Occurrence of Unsolicited Symptoms During a 30-day Surveillance Period Following Vaccinations at Days 0, 30, and 60. The number of participants spontaneously reporting any symptom (defined as any Adverse Event considered associated with the product) within 30 days of any vaccination. Participants are counted only once but may have experienced events on multiple occasions. Day of vaccination and 30 subsequent days. Yes
Primary Number of Subjects Spontaneously Reporting Any Serious Adverse Event. Any untoward medical occurrence that resulted in death, persistent/significant disability/incapacity, required in-patient hospitalization or prolongation thereof, was life threatening or a congenital anomaly/birth defect in offspring of a study subject; or may have jeopardized the participant or required intervention to prevent one of the outcomes. 1 year after the last vaccination. Yes
Primary Occurrence of Solicited Local Symptoms During a 7-day Surveillance Period (Systematically Collected) Following Vaccinations at Days 0, 30, and 60. The number of participants reporting pain, swelling and erythema. Participants are counted only once but may have experienced symptoms on multiple occasions. 7 Days following any vaccination Yes
Secondary Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 0 This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA. Day 0 No
Secondary Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 30 This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA. Day 30 +/- 7 days No
Secondary Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 60 This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA. Day 60 +/- 7 days No
Secondary Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 90 This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA. Day 90 +/- 10 days No
Secondary Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 180 This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA. Day 180 +/- 14 days No
Secondary Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 272. This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA. Day 272 +/- 14 days No
Secondary Anti-FMP2.1 Antibody Titers Measured by ELISA, at Day 364 This outcome is the mean of the log anti-FMP2.1 antibody response measured by ELISA. Day 364 +/- 14 days No
See also
  Status Clinical Trial Phase
Completed NCT04577066 - Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites. Phase 1/Phase 2
Completed NCT01883609 - A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S Phase 1/Phase 2
Completed NCT00593398 - Malarial Immunity in Pregnant Cameroonian Women
Completed NCT01659281 - Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand N/A
Completed NCT00074841 - Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India Phase 2/Phase 3
Recruiting NCT04416945 - Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic N/A
Completed NCT00314899 - Fetal Immunity to Falciparum Malaria
Completed NCT02867059 - SJ733 Induced Blood Stage Malaria Challenge Study Phase 1
Completed NCT00701961 - Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy Phase 2/Phase 3
Completed NCT00338520 - Hyperphenylalaninemia in Cerebral Malaria N/A
Completed NCT00707200 - The Cytoadherence in Pediatric Malaria (CPM) Study N/A
Completed NCT00393757 - Malaria Transmission and Immunity in Highland Kenya
Completed NCT03783299 - Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic Phase 4
Completed NCT02614404 - Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria Phase 1
Completed NCT00730782 - Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers Phase 1
Completed NCT00349713 - FMP2.1 Trial in Bandiagara, Mali Phase 1
Recruiting NCT05052502 - Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand N/A
Completed NCT04093765 - Mass Screening and Treatment for Reduction of Falciparum Malaria N/A
Completed NCT03764527 - Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar Phase 4
Completed NCT03773536 - Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar Phase 4